+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying farletuzumab ecteribulin MORAb-202, a folate receptor alpha-targeting antibody-drug conjugate, in participants with selected solid tumors including ovarian cancer, endometrial cancer, non-small cell lung carcinoma, and triple-negative breast cancer. The study aims to evaluate safety, tolerability, and determine recommended doses in early phases, then assess preliminary effectiveness and further safety in later phases. Various treatment regimens and combinations with lenvatinib are also being explored to optimize dosing. Participants receive farletuzumab ecteribulin intravenously every three weeks in 21-day cycles. Some groups receive additional oral corticosteroids after each dose or different infusion schedules within the cycle. In one part, ovarian cancer participants receive either farletuzumab ecteribulin alone or combined with oral lenvatinib. The study includes dose escalation, dose confirmation, and dose optimization parts with separate cohorts for specific tumor types and treatment regimens. During the study, participants undergo regular assessments including tumor imaging to measure response, laboratory tests, vital signs, and ECGs to monitor safety. Researchers track adverse events, dose-limiting toxicities, and pharmacokinetics of the study drug. Outcome measures include objective response rate, duration of response, progression-free survival, overall survival, and clinical benefit rates, with follow-up lasting up to approximately five years after treatment initiation.

Age: 18Years +All GendersPhase 1Phase 2
58 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
S

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with ALK gene rearrangement treated with next-generation tyrosine kinase inhibitors TKIs as first-line therapy. This prospective study, part of the national EXPLORE ALK cohort, aims to understand the biological characteristics and resistance mechanisms of this cancer type. It involves patients with stage IIIB or IV NSCLC who are not eligible for curative locoregional treatment and have confirmed ALK rearrangement. The study collects tumor tissue samples at diagnosis and at disease progression, if available, to analyze ALK fusion partners, variants, and co-mutations using RNA sequencing. Blood samples are taken at diagnosis, first tumor evaluation, and disease progression to analyze circulating tumor DNA ctDNA with next-generation sequencing. Treatments studied include alectinib, brigatinib, lorlatinib, and entrectinib, either marketed or under early access programs. Participants provide blood samples and allow use of tumor tissue for centralized biological analyses. Researchers measure progression-free survival up to 72 months as the primary outcome, along with overall survival, response rates, duration of response, ctDNA clearance, and resistance mechanisms associated with treatment and ALK fusion partners. The study involves regular evaluations over several years to monitor treatment outcomes and biological changes.

Age: 18Years +All GendersPhase Not Applicable
46 locations
A

Actively Recruiting

Researchers are studying patients with community-acquired pneumonia who need oxygen therapy due to acute respiratory distress and low blood oxygen levels. This research aims to see if placing patients in a prone position lying face down while they receive nasal high flow oxygen can reduce the need for intubation and improve outcomes. The study particularly excludes patients with COVID-19 and focuses on non-COVID pneumonia cases. Participants will be randomly assigned to one of two groups. One group will be encouraged and assisted to lie in the prone position for at least 8 hours per day in multiple sessions, aiming for up to 16 hours if tolerated. The other group will receive usual care with nasal high flow oxygen therapy but no prone positioning. Both groups will have oxygen levels monitored and care adjusted to maintain target oxygen saturation. During the study, patients will be observed for intubation rates within 28 days, comfort levels during prone positioning, oxygenation changes, time to escalation of breathing support, and overall outcomes including mortality up to 90 days. Safety measures like skin and infection monitoring will also be recorded. Quality of life will be assessed at 90 days and 5 years, with nursing workload tracked within the first day after randomization.

Age: 18Years +All GendersPhase Not Applicable
38 locations
M

Actively Recruiting

Researchers are studying muscle dysfunction that develops in about 40% of patients during intensive care, especially those with sepsis. This muscle injury affects both limb and respiratory muscles, leading to weakness and difficulties in weaning from mechanical ventilation. The rapid loss of muscle mass during ICU stay is linked to the severity of illness and can negatively impact long-term survival, physical function, and quality of life. Preventive and therapeutic strategies are needed due to the lack of clear evidence for effective treatments. Participants receive standard ICU care without changes to early mobilization, physiotherapy, exercise, or nutritional management. Their muscle condition is monitored over time during ICU stay and after discharge through multiple scheduled visits up to 90 days. Assessments include clinical evaluations, ultrasound imaging, electroneuromyography, and blood tests to measure inflammation and organ function. Additional evaluations after ICU discharge cover physical ability, cognitive function, mood, and nutritional status. Throughout the study, participants undergo seven visits during ICU stay and one follow-up visit at day 90. Muscle strength is measured using the Medical Research Council score and other tests like handgrip with electromyography and diaphragmatic ultrasound. Researchers also assess organ dysfunction and inflammation via blood samples. Functional tests such as the 6-minute walk and cognitive assessments are performed at the study end to understand long-term outcomes. The total study duration for each participant is up to 90 days.

Age: 18Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

This observational study involves patients diagnosed with chronic myelomonocytic leukemia, a type of leukemia characterized by increased monocytes in the blood. The purpose is to better understand the diseases underlying mechanisms, with data collected over an average of 15 years. Biological samples and anonymized data will be gathered during routine care or clinical trials to support this research. The study is sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Participants will have biological samples collected, including blood and bone marrow, during scheduled medical assessments. Blood samples include standard tubes and may vary based on research needs, while bone marrow samples are taken during routine myelograms. In exceptional cases, tissue samples may be collected during surgical procedures if agreed upon with the surgeon. These collections occur alongside usual medical care without additional interventions. Throughout the study, participants will undergo sample collections aligned with their medical visits and tests. Researchers will analyze these samples and associated anonymized data to study the diseases pathophysiology. Participation involves no investigational treatments, and the study will monitor participants for up to 15 years to gather long-term data. Safety and routine care continue as usual during this period.

Age: 18Years +All Genders
24 locations
O

Actively Recruiting

Researchers are studying acute hidrosadenitis to better understand its different types or phenotypes. This is important because recognizing these subtypes can help tailor more suitable treatments and care. The study aims to define the natural history of the disease and identify environmental factors linked to its chronic form over an average period of three years. This is an observational study where no treatments or interventions are tested. Instead, patients diagnosed with acute hidrosadenitis are followed over time to observe their condition. The study collects detailed information about the clinical forms of the disease and tracks how it progresses in patients. Participants will be monitored for about three years during which researchers will record data about their disease severity, clinical characteristics, and environmental exposures. The main outcomes measured include the different clinical forms of hidrosadenitis and factors that may influence chronic disease development. There is no specific treatment given rather, the study observes patients to gather valuable information for future care approaches.

All AgesAll Genders
13 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
P

Actively Recruiting

Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.

Age: 18Years - 69YearsAll GendersPhase 3
69 locations
E

Actively Recruiting

Researchers are evaluating whether a personalized rehabilitation program that combines nutrition, physiotherapy, and physical activity, started early in the intensive care unit ICU and continued through hospital discharge and at home, can improve long-term outcomes for patients who have undergone invasive mechanical ventilation and vasopressor therapy. This trial compares this early extended rehabilitation approach to usual care, which involves standard nutritional support and physiotherapy provided according to local ICU practices. Participants will be randomly assigned to either the individualized rehabilitation group or the usual care group. The rehabilitation group will receive a tailored program involving dieticians, physiotherapists, and physical activity instructors, with the intervention continuing for 12 weeks from ICU admission through post-ICU wards and at home. The usual care group will receive standard nutritional and physiotherapy support from day 0 to day 180. Throughout the study, participants will undergo various assessments including physical activity levels, muscle strength, muscle mass, body weight, and quality of life measured at multiple time points up to 12 months after randomization. The primary outcome is the distance walked in six minutes at 6 months. Researchers will also track mortality rates, glucose control, insulin usage, infection rates, and hospital stay lengths. The total participation may last up to 12 months with follow-up evaluations during this period.

Age: 18Years +All GendersPhase Not Applicable
52 locations

1-10 of 23

1